AI tools for IP that are expert-led, pharma-specific and client-centric
AI is one tool in our toolbox for helping us with our core mission of assisting pharmaceutical companies in bringing innovative medicines to market to give hope to patients.
At Evolve, we are focused on using AI in a way that will truly add value to our clients. We have developed our own AI tools and workflows that are tailored to the unique requirements of pharmaceutical and biotech IP. As a specialised and agile firm devoted to pharmaceutical and biotechnology, we possess deep domain knowledge of life science patents and practical experience developing our own in-house AI solutions. We tailor our AI workflows and tools to the needs of our clients and the unique challenges of the pharmaceutical sector.
At Evolve, we have therefore chosen to build our own AI solutions as opposed to rely on third-party software providers providing generalised off-the-shelf solutions. We strongly believe that AI solutions for the patent industry need to be expert-led and aligned with the requirements of specific technical fields.
A Complete AI Ecosystem for Pharma IP
Our clients benefit from Evolve’s wider suite of bespoke AI agents. These include:
- Darwin: Pharm IP-focused patent drafting.
- Popper: Global patent prosecution AI for pharmaceutical IP
- Cassandra: Contract review for pharma and biotech licences,
- Einstein: Validity analysis, including priority claims, added matter assessment, novelty, inventive step and sufficiency,
- Ammonite Charts, our proprietary patent portfolio visualisations for competitive landscaping and communicating IP strategy,
- Franklin: Publication and invention disclosure review.
The patent profession is entering a new era of technological capability. At Evolve, we offer a strategic fractional partnership that combines bespoke AI for pharmaceutical IP with our own deep industry expertise.
Our clients come first
Our use of AI follows our strict professional code of conduct as patent attorneys, including maintaining the highest level of confidentiality and data security for our clients’ data. Our sophisticated workflows also ensure that all client work products generated by AI remain meticulously reviewed, interpreted, and verified by a qualified patent attorney. Additionally, we will only use generative AI in connection with a client’s confidential information after establishing consent.
Learn more
If you would like to hear more about how we are leveraging AI technology to secure robust patent protection for our clients, or would like to discuss potential collaborations, please contact a member of our team. We would love to hear from you!
Read more about how we are leveraging AI to increase value for clients on our Evolve Insights blog.
The Experts
Rose Hughes, MA (Cantab), PhD, EPA
Rose is a biotech and pharmaceutical patent specialist with over a decade of experience in intellectual property. Rose is a patent attorney at Evolve, where she leverages our unique fractional in-house model to provide clients with deep patent law expertise combined with the strategic commercial oversight typically associated with senior in-house counsel.
With a PhD in Immunology from UCL, Rose applies her technical background to complex innovations in biologics, cell and gene therapies, and the rapidly emerging field of AI-assisted drug development. Previously, Rose held the role of Director. Patents at AstraZeneca, where she was responsible for global IP portfolios and IP strategy at every stage of the pharmaceutical pipeline, from platform development and on-market commercialization to SPCs and patent term extensions.
A recognized thought leader in the field, Rose has been a regular contributor to IPKat since 2018, offering practical insights into European patent law developments. She is Editor of the CIPA Guide to the Patents Act (10th Edition), a frequent speaker on the epi podcast, a guest lecturer for the Brunel University IP law Postgrad Certificate, and a contributing author to published books A User’s Guide to Intellectual Property in Life Sciences (2021) and Developments and Directions in Intellectual Property Law (2023).
Steven Gurney, EPA, CPA, MIPLaw
Steven is focused on maximising the potential of his pharmaceutical and life science clients. As the founder of Evolve Intellectual Property in 2021, he brings a passion for developing robust IP strategies and providing expert counsel.
A highly skilled life science patent attorney with over 20 years of combined in-house and private practice experience, Steven is qualified as a European, UK, and Australian patent attorney. His recognition in legal directories includes LEGAL 500 (2024, 2025), IP STARS (2024, 2025), and IAM Patent 1000 (2024).
Steven’s expertise spans pharmaceuticals, drug development and IP, drafting, portfolio management and prosecution, lifecycle management, licensing (in- and out-), due diligence and FTO, contentious work (including litigation and opposition), and regulatory exclusivities like PTE/SPC.
